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Review
Evaluation of state and trait biomarkers in
healthy volunteers for the development of
novel drug treatments in schizophrenia
Ivan Koychev1, Emma Barkus2,3, Ulrich Ettinger4, Simon Killcross5,
Jonathan P Roiser6, Lawrence Wilkinson7 and Bill Deakin1
Abstract
Antipsychotic drugs are the mainstay of treatment for schizophrenia but they have little effect on core negative symptoms or cognitive impairment. To
meet the deficiencies of current treatments, novel potential compounds are emerging from preclinical research but translation to clinical success has
been poor. This article evaluates the possibility that cognitive and physiological abnormalities in schizophrenia can be used as central nervous system
biomarkers to predict, in healthy volunteers, the likely efficacy of entirely new pharmacological approaches to treatment. Early detection of efficacy
would focus resource on rapidly developing, effective drugs. We review the relevance of selected cognitive and physiological abnormalities as
biomarkers in schizophrenia and three of its surrogate populations: (i) healthy volunteers with high trait schizotypy; (ii) unaffected relatives of
patients; and (iii) healthy volunteers in a state of cortical glutamate disinhibition induced by low-dose ketamine. Several biomarkers are abnormal in
these groups and in some instances there has been exploratory work to determine their sensitivity to drug action. They are generally insensitive to
current antipsychotics and therefore their predictive validity cannot be established until novel, therapeutically useful drugs are discovered. Until then
such biomarker studies can provide evidence of drugs engaging with the mechanism of interest and encouragement of the concept.
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Background and rationale for using
biomarkers in drug development for
schizophrenia
The introduction of the first antipsychotic, chlorpromazine, in
1952 and the subsequent generation of typical and atypical D2
antagonists saw a dramatic improvement in the prognosis of
schizophrenia and enabled the de-institutionalization of
patients to care in the community. However, many patients
continue to experience symptoms in addition to the burden
imposed by central nervous system (CNS) and metabolic side
effects. Most patients change their treatment within the first 18
months (Lieberman et al., 2005). Furthermore, the efficacy of
current treatments is largely confined to reduced psychotic or
positive symptoms, with limited efficacy on negative and deficit
symptoms or on impaired cognitive function. Poor social and
occupational functioning (Heinrichs, 2005) remains a common
outcome. Finding new pharmacological approaches to tackle
these deficits remains a major unmet need in the treatment of
schizophrenia (Nuechterlein et al., 2008). In addition little
progress has been made on a truly disease-modifying therapy
that has the potential of preventing schizophrenia.
Scientific insights in cognitive neuroscience, neuropharma-
cology and genetics are producing an increasing number of
novel drug targets. This is matched by increasing numbers of
candidate compounds through technological advances such
as combinatorial chemistry and high-throughput screening
(Hurko, 2009). Novel drug development has mostly focused
on compounds affecting single neurotransmitter systems
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putatively implicated in the pathogenesis of schizophrenia
(Roth et al., 2004). The main targets and compounds for
improving cognition in schizophrenia involve glutamate
(e.g. glycine, metabotropic, AMPA receptor modulators; gly-
cine transporter antagonists), acetylcholine (muscarinic
and a7-nicotinic receptor agonists), dopamine (e.g. D1
and D3 receptor agonists; D4 receptor antagonists; cate-
chol-O-methyltranferase inhibitors) and serotonin (e.g.
5-[hydroxytryptamine]HT2A and 5-HT6 receptor antagonists;
5-HT1A and 5-HT4 receptor agonists) neurotransmitter sys-
tems (Gray and Roth, 2007). However, the increase in targets
and new chemical entities has not so far translated into clin-
ical efficacy. Most novel compounds fail at the initial tests of
efficacy in human disease, phase 2 and 3 clinical trials (Hurko,
2010). A recent review showed that practically all the agents
that are currently in phase 3 clinical trials have the same
mechanism as the already available agents (D2 antagonism)
(Gray and Roth, 2007).
Obstacles to novel drug development in schizophrenia
The high attrition rate for novel compounds has exposed
several critical obstacles to drug development for psychiat-
ric illnesses that may be particularly relevant to the develop-
ment of an antipsychotic with potent cognitive enhancing
action.
First, novel agents are classically screened on the basis of
their molecular actions and efficacy in animal behavioural
models. However, only 3–5% of the compounds that were
effective in preclinical screens were launched on the market
(Hurko, 2010). This suggests that while animal models may
capture aspects of the main disease process, they are still far
from being its reliable and precise replication (Marcotte et al.,
2001).
Second, once a drug is introduced to a clinical population,
its efficacy is assessed using traditional clinical end-points,
such as clinical rating scales. Their sole dependence on the
patients’ reports and clinician’s observations introduces a
subjective element that reduces their sensitivity and precision
(Jansson and Parnas, 2007). In addition, these end-points
account poorly for the cross-ethnic differences in psychopa-
thology (Brekke and Barrio, 1997), which makes international
comparisons difficult. This has been further complicated by
high placebo response rates, which are particularly problem-
atic in clinical trials in psychiatry (Kemp et al., 2010; Kinon
et al., 2011). All these factors obscure the true drug effects and
inflate the sample sizes required to detect clinical efficacy in
clinical trials.
The final and perhaps most important obstacle to novel
drug development in schizophrenia is a conceptual one. In
contrast to many physical diseases, the aetiology of schizo-
phrenia remains unknown which makes the choice of appro-
priate targets for drug development especially risky. Several
neurotransmitter systems have been implicated in the patho-
genesis of psychosis but, as mentioned previously, few drugs
targeting non-dopaminergic transmitters show evidence of
efficacy (Miyamoto et al., 2005). Given the probable complex
components in schizophrenia, attributing the disease to a dis-
turbance in a single neurochemical system is likely to prove
too simplistic (Roth et al., 2004).
Increasing the probability of technical success
using biomarkers
The need to improve the probability of technical success of
drug development has driven the identification and validation
of biomarkers. A biomarker is defined by the United States
Food and Drugs Administration (FDA) as ‘A characteristic
that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or phar-
macological responses to a therapeutic intervention’
(www.fda.gov). Biomarkers have the potential of augmenting
the chances of successful drug development through better
target validation, provision of surrogate end-points and
patient segmentation (Breier, 2005).
Target validation. Biomarkers relevant to target validation
probe either disease-specific or drug activity processes. Disease
biomarkers are used to explore the biological mechanisms
involved in the pathophysiology of disease. This information
can then be used to improve the diagnosis of the condition, to
mark its progression and to develop pathophysiologically rel-
evant animal models. For instance, the finding of decreased
TD4 cells in HIV gave not only an insight into the pathophys-
iology of the condition, but also provided a practical measure
to track its outcome. Drug activity biomarkers provide infor-
mation on whether the drug interacts effectively with its target
in humans (Breier, 2005).
Clinical surrogates. Biomarkers that consistently predict
traditional clinical end-points could replace them and
become ‘clinical surrogates’. Clinical surrogates, being inher-
ently more precise, reliable and replicable than traditional
end-points, could allow the detection of efficacy in smaller
clinical trials. Also, classical clinical end-points, such as
survival and quality of life, inevitably require long-term
follow-up. If a clinical surrogate predicts long-term treatment
outcomes, however, it could reduce the duration of studies
testing long-term benefit. Examples of successful clinical sur-
rogates include blood cholesterol (predictor of cardiovascular
mortality) and solid tumour size (predictor of mortality from
a neoplastic cause). The MATRICS (Measurement and
Treatment Research to Improve Cognition in
Schizophrenia) initiative has been developing a cognitive bat-
tery with the goal of providing of clinical surrogates for trials
of cognitive enhancing drugs (Buchanan et al., 2007).
Patient segmentation. Some biomarkers also have the
potential to stratify patients according to their likely
treatment response or sensitivity to side effects. Utilizing
such biomarkers could help reduce the sample sizes of
clinical trials by allowing selection of more homogeneous
patient populations in phase 2 and 3 clinical trials, which
in turn reduces the variability of treatment response and
decreases the likelihood of study discontinuation due to
side effects.
Uncovering the likely drug failures using biomarkers
Biomarkers could improve the chances of technical success of
a drug by refining its targets, allowing its specific and precise
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assessment and selecting patient groups that are most likely to
benefit. However, in the current situation of unclear patho-
physiology of the main disease process, the vast majority of
novel schizophrenia compounds are destined to fail.
Therefore, a mechanism is needed to determine the likely fail-
ures as early as possible in their development and redirect
resources to more promising compounds. This ‘quick win,
quick kill’ approach aims to identify the likely failures as
early as the phase I registration trial (Breier, 2005). Central
to this idea are proof of concept studies which function by
selecting only a subgroup of patients that is more likely to
respond or by recruiting groups of individuals that have only
limited symptom profile, that is, surrogate populations
(Hurko, 2009). Proof of concept studies precede the costly
phase 2 clinical trials which use more rigid diagnostic criteria,
heterogeneous populations and traditional clinical end-
points.
Biomarkers are a key component of this strategy, as they
can provide the precise assessment of efficacy that these clin-
ical trials of small sample size and short duration require.
The biomarkers for phase 1 ‘proof of concept’ studies are
used to guide internal decision-making and early resource
allocation and therefore do not need to undergo the same
level of validation as clinical surrogates. Instead, their use-
fulness is determined by their sensitivity to the disease pro-
cess (both in patients and in surrogate populations) and to
the action of drugs that a prospective compound is aiming
to emulate.
Biomarkers in surrogate populations
Surrogate populations are defined as groups that feature a
component of the main disease process but do not have the
fully developed condition. Many medical disorders can be
seen extremes of normally distributed functions such as
blood-pressure in hypertension and glucose regulation in dia-
betes. In psychiatry, anxiety and depressive neuroses have
long been viewed as extremes of normal variation in fearful-
ness and mood. The idea that psychoses may represent
extremes of normally distributed cognitive functions – such
as reward processing (aberrant salience hypothesis), percep-
tion (hallucinations extended from vivid mental imagery) and
frontal lobe executive function – is gaining momentum. The
continuum view of physical and psychiatric disorders is
encouraged by the absence of major gene effects, suggesting
that many genes of small effect contribute to risk. This
increases the likelihood that many individuals in the general
population will have some of these genes and therefore may
express some of the phenotype associated with the full
disease.
The appeal of proof-of-concept biomarker studies in sur-
rogate populations lies in their practicality, as they involve
populations that are easier to recruit than homogeneous
patient groups and lack the major confounding factors of
patient samples. In respect to cognition in schizophrenia,
such potentially confounding factors are prior or concomitant
drug treatment, chronicity, lack of cooperation, lower educa-
tional and premorbid intelligence quotient (IQ) levels. At the
same time biomarkers in these samples may be more sensitive
to drug effects than unselected healthy volunteers because
they share elements of the disorder. In addition, these samples
provide the option of testing potentially disease-modifying
therapies, as they feature the vulnerability pattern, but not
the fully developed disease.
The authors have been interested in the strategy to
improve the sensitivity of biomarkers for drug action by
evaluating them in three surrogate groups with increased
psychosis liability: (i) unaffected relatives because they
share genetic vulnerability, (ii) people with schizotypal per-
sonality because of their predisposition to symptoms, and
(iii) volunteers with experimental drug-induced schizophre-
nia-like states.
Biomarkers in relatives: endophenotypes
and vulnerability
One healthy group who might show greater sensitivity to
novel schizophrenia treatments are the unaffected first-
degree relatives of patients with schizophrenia, since they
will carry more susceptibility genes than found in the general
population, but in insufficient number or combination to
develop psychosis or to overcome unknown protective fac-
tors. Several neurocognitive characteristics that are shared
between relatives and patients have been reported (Allen
et al., 2009) and some are described in later sections. These
changes imply the presence of shared susceptibility genes and
lie closer to genetic mechanisms of disease than the overt
clinical phenotype. Therefore, these biomarkers are a sub-
group of the disease-specific biomarkers that relate to genetic
vulnerability only. With the inclusion of a number of other
criteria they have been termed endophenotypes (Gottesman
and Gould, 2003).
In the psychosis literature they have principally concerned
cognition or information-processing. Successful identification
of endophenotypes could reveal neural pathways that under-
lie the schizophrenia phenotype. However, selecting volun-
teers for drug-efficacy biomarker studies on the basis of
familial liability will require both openness and tact to
avoid understandable fears of being treated like their ill rela-
tives and identified with disorder. Drugs that prove effective
on biomarkers in relatives would have the potential to affect
mechanisms of vulnerability and therefore prevent onset of
disorder in those with at-risk mental states. There is some
tentative evidence that relatives of patients with schizophrenia
who express psychosis liability characteristics, benefit func-
tionally from treatment with a low-dose atypical antipsy-
chotic (e.g. Tsuang et al., 1999).
Biomarkers in schizotypy: correlates
of psychopathology
In keeping with the continuum view of schizophrenia, system-
atic surveys suggest that brief schizophrenia-like experiences
and beliefs are surprisingly common in the general population
and are also more prevalent among first-degree relatives of
patients (Van Os et al., 1997). Such phenomena may be suf-
ficiently intense and long-standing to interfere with everyday
functioning and so warrant the diagnosis of schizotypal
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personality disorder. However, much evidence suggests that
schizotypal personality traits are continuously distributed in
the general population and that schizotypal traits may be
quite prevalent in people with normal social and occupational
functioning. In a later section we discuss evidence that healthy
volunteers with high scores on schizotypal personality ques-
tionnaires show patterns of neurocognitive performance sim-
ilar to these seen in schizophrenia. Selecting schizotypal
populations may enhance the sensitivity of drug efficacy bio-
marker studies in the healthy population. Indeed, schizotypal
symptoms themselves may be sensitive to new antipsychotic
drugs and benefit from such interventions.
Biomarkers in drug-induced states
Dopamine. Administration of dopamine-releasing agents
such as amphetamine and methylphenidate has been used
extensively to model the symptoms of schizophrenia. These
agents induce an acute schizophrenia-like syndrome in heavy
users (Connell, 1958), exacerbate positive symptoms in
patients (although improvements in spontaneity and activa-
tion have also been reported), and induce symptoms when
given experimentally to volunteers. However, high doses are
required to induce paranoid ideation and hallucinations and
acute doses do not reproduce the cognitive and negative
symptoms of schizophrenia. These findings, along with the
demonstration that antipsychotic drugs block the behavioural
effects of amphetamine gave rise to the theory that antipsy-
chotics work through dopamine antagonism and the corollary
hypothesis that schizophrenia is due to excessive dopaminer-
gic neurotransmission. That enhanced dopamine release
occurs in schizophrenia has now been firmly established by
positron emission tomography (PET) measuring dopamine
displacement of D2 radioligand binding (Abi-Dargham
et al., 2000; Laruelle et al., 1996). Reports of increased
uptake of fluoroDOPA suggest presynaptic dopamine neu-
rones are more active in both acute and prodromal patients
(Howes et al., 2009; McGowan et al., 2004). However, only
subcortical striatal dopamine function has been quantifiable
with these techniques and indirect evidence suggests that fron-
tal cortical dopamine release may be reduced in schizophre-
nia. Indeed an important theory suggests that the primary
abnormality in schizophrenia may be decreased frontal dopa-
mine function with secondary increases in subcortical dopa-
mine (Davis et al., 1991; Weinberger et al., 1988), the former
mediating impaired cognition and negative symptoms, and
the latter, positive symptoms.
How increased striatal dopamine release translates into
positive symptoms is not clear. Dopamine clearly has an
important role in reward in which its release by unexpected
rewards (reward prediction error) triggers new learning. This
has been visualized in humans, for example, in a study in
which reward prediction error was associated with activity
in dopamine areas that was attenuated by the dopamine
antagonist haloperidol and facilitated by the dopamine pre-
cursor L-DOPA (Pessiglione et al., 2006). Excessive dopa-
mine release in schizophrenia is postulated to result in
aberrant reward learning and the formation of positive
symptoms (Kapur, 2003). Biomarkers based on reward pre-
diction error are discussed in a later section.
Dopamine modulates frontal executive function and work-
ing memory (Goldman-Rakic, 1994). However, the relation-
ship may not be linear. Literature on studies with animals and
humans suggests that enhancing dopamine function from a
low baseline improves executive functions, whereas increases
beyond an optimal level result in decreases in executive func-
tion, therefore suggesting an inverted U-shape relationship.
A further complication is that D1 and D2 receptors may exert
opposite influences on frontal executive function. The empir-
ical evidence suggests acute amphetamine challenge improves
rather than disrupts cognition in patients with schizophrenia
(Pietrzak et al., 2010). The improvement may be explained by
a reversal of deficient stimulation of D1 receptors in schizo-
phrenia that predominate in frontal cortex. As a result of this
development, the experimental application of acute amphet-
amine challenge has recently shifted towards improving per-
formance in states of suboptimal cognition and this is
reviewed in later sections.
It should also be noted that differences exist between the
effects of acutely and chronically administered amphetamine.
Repeated administration of amphetamine in experimental
animals can result in increased hyperactivity responses and
other effects of amphetamine. This is known as amphetamine
sensitization and has been proposed as a model for schizo-
phrenia. Furthermore, sensitized animals also show evidence
of cognitive deficits. Limited evidence suggests that amphet-
amine sensitization can be demonstrated in healthy volunteers
and further exploration of cognitive biomarkers in this para-
digm would seem worthwhile. It might be possible, for exam-
ple, to find drugs that prevent sensitization without blocking
the effect of amphetamine, and these might be useful preven-
tative treatments in high-risk groups (Featherstone et al.,
2007).
Corollary hypothesis acetylcholine. Administration of the
dissociative anaesthetic agent ketamine in sub-anaesthetic
doses to healthy volunteers induces suspiciousness, thought
disorder, some of the negative symptoms of schizophrenia
and impairs performance on working memory (Deakin
et al., 2008; Krystal et al., 1999; Pomarol-Clotet et al.,
2006). Ketamine blocks the ion channel associated with the
N-methyl D-aspartate (NMDA) glutamate receptor. The psy-
chotomimetic effects of NMDA channel blockers gave rise to
the glutamate deficiency theory of schizophrenia. However,
this is now better termed the NMDA deficiency hypothesis
because drugs such as ketamine produce a paradoxical disin-
hibition of cortical glutamate release that acts on non-
NMDA receptors. Many of the subjective and behavioural
effects of ketamine can be blocked by agents that decrease
glutamate release (Deakin et al., 2008). Thus increased gluta-
mate release may be responsible for psychosis-like symptoms
after ketamine, as has been suggested for the symptoms of
schizophrenia (Deakin and Simpson, 1997). Whether there is
a primary loss of NMDA receptors in schizophrenia is not
clear, although this has been described in post-mortem hip-
pocampus and in an in-vivo radioligand-binding study using
1210 Journal of Psychopharmacology 25(9)
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single positron emission tomography (Law and Deakin, 2001;
Pilowsky et al., 2006).
The NMDA deficiency theory of schizophrenia has
recently become pleasingly unified with gamma-aminobuty-
ric acid (GABA) deficiency theories by evidence that a sub-
class of GABA interneurones that synchronizes the firing of
pyramidal neurones is driven primarily by NMDA receptors
(Belforte et al., 2010). These so-called fast-spiking interneur-
ones are thought to correspond to these containing parval-
bumin, which have repeatedly been reported to be deficient
in post-mortem brain in schizophrenia (Lewis and
Moghaddam, 2006). Thus ketamine and related drugs may
mimic NMDA hypofunction, impaired GABA neurotrans-
mission and disinhibited glutamate release which is hypoth-
esized to occur in schizophrenia. In-vivo methods of
quantifying GABA and glutamate function are needed to
test these theories.
The cholinergic system has also been implicated in drug-
induced psychotics. The administration of anticholinergic
agents, such as scopolamine or atropine, is known to have
the potential of causing ‘antimuscarinic psychosis’, a state
that shares some of the behavioural features of endogenous
schizophrenia (Minzenberg et al., 2004; Perry and Perry,
1995; Perry et al., 1978). Procyclidine, another antimuscarinic
agent, was shown to retard the antipsychotic effects of flupen-
tixol in patients (Johnstone et al., 1983). Together with data
showing alterations of the muscarinic and nicotinic receptors
in schizophrenia (Terry, 2008), this evidence has suggested
that the acetylcholine system may be important in the path-
ogenesis of schizophrenia. Cognition is a likely target of a
cholinergic disturbance (Minzenberg et al., 2004), as this neu-
rotransmitter system is known to play an important modula-
tory role in memory, learning and synaptic plasticity (Sarter
and Bruno, 1997). In demonstration of this, the use of cho-
linesterase inhibitors such as donezepil in Alzheimer’s disease
has been linked to slowing of the progression of cognitive
deficits in this condition (Birks, 2006). Unlike ketamine, how-
ever, procyclidine and other antimuscarinic agents are limited
in their use as pharmacological models of schizophrenia
owing to their unfavourable side effects profile.
Purpose of the review
The second part of this article reviews the validity of several
neurocognitive biomarkers from the major areas of interest in
the literature with some more novel potential biomarkers
developed by the authors. The emphasis is on potential bio-
markers of drug efficacy in healthy volunteers that could be
used in large-scale multicentre studies. We focus on neuro-
cognition because it is free of preconceptions about the neu-
rochemical actions necessary for efficacy of a new drug and
the need for treatments that improve cognition and negative
symptoms. Functional brain imaging using positron emission
tomography (PET) and functional magnetic resonance imag-
ing (fMRI) is informative at identifying the involvement of
neural systems in cognitive functioning. Neuroimaging is
therefore showing promise as a modality for detecting drug-
efficacy but there are many technical issues and it is beyond
the scope of this article to provide a meaningful review of
imaging biomarkers.
The review assesses selected neurocognitive biomarkers
according to their:
. reliability (consistent effects reported by different labora-
tories or over time);
. criterion validity (abnormal in criterion groups: patients,
unaffected relatives, high schizotypes and after amphet-
amine or ketamine in healthy volunteers);
. predictive validity (sensitive to the action of compounds
effective in schizophrenia or cognition); and
. construct validity (relates to a known neurobiological
system implicated in the disorder).
The importance of establishing the reliability and sensitivity
of cognitive tests as end-points for clinical trials in schizophrenia
has been recognized by the MATRICS initiative (Harvey et al.,
2010).However, these studies focus solely on samples of patients
with schizophrenia and the results are useful in terms of selecting
and standardizing reliable cognitive tasks as clinical end-points.
However, as discussed previously, the various confounds in this
group (chronic disease and treatment, polypharmacy, institu-
tionalization, florid positive symptoms, reduced cooperation)
limit the conclusions that can be drawn regarding the patho-
physiology of the subtle cognitive deficits and the disease. In
an attempt to address these limitations, MATRICS recom-
mends that participants have not more than moderate scores
on formal thought disorder, hallucinations and delusions, neg-
ative and depressive symptoms, have minimal extrapyramidal
symptoms, have been maintained on the same dose for 2–4
weeks and take only one antipsychotic (http://www.matrics.u-
cla.edu/matrics-recommendations-frame.htm). This limits the
number of appropriate participants and still does not fully
account for all confounds. In this review, the focus is on healthy
volunteer criterion groups that provide a different viewpoint of
the pathophysiology (genetic, psychopathological and molecu-
lar) with little or no impact of these confounding factors. This
approach may contribute to our understanding of the mecha-
nisms behind cognitive abnormalities in schizophrenia and
accelerate the early evaluation of novel drug treatments.
Another relevant project is the CNTRICS (Cognitive
Neuroscience Treatment Research to Improve Cognition in
Schizophrenia) initiative (Carter and Barch, 2007) which aims
to identify promisingmeasures of perception and integration for
validation as biomarkers for pathogenesis and drug develop-
ment. One mature measure that already meets many
CNTRICS criteria is pre-pulse inhibition of the startle response
(Green et al., 2009). The literature, including many studies in
healthy criterion groups has been extensively reviewed and is
therefore not considered further here (Swerdlow et al., 2008).
We begin with working memory, one of the MATRICS
domains, since a number of studies have explored abnormal-
ities and drug effects in healthy criterion groups. We include
some less well-validated tasks involving learning and percep-
tion that have an interesting theoretical background. From
the extensive literature on eye-movement control and EEG
biomarkers in schizophrenia, we have focused on newer mea-
sures and findings.
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Validity of cognitive and physiological
biomarkers of cognitive processes related
to schizophrenia
Working memory: N-back and spatial working memory
Working memory (WM) refers to a process for holding and
managing information ‘online’ over short periods of time,
allowing its manipulation and usage in reasoning, compre-
hension and decision-making. The distinction between
short-term memory and working memory is subtle and not
always consistent (Reichenberg and Harvey, 2007). Working
memory generally implies that the information is both stored
and manipulated. It has been proposed that separate systems
for the maintenance of verbal and visuo-spatial information
exist (Baddeley, 1986). In accordance, the working memory
tasks used in schizophrenia research as a rule involve either of
the two modalities (Lee and Park, 2005).
Paradigm description. In the N-back task, a series of digits
is presented and participants are required to respond if the
current digit is the same as one presented N trials previously,
where N varies between 0 and 3 in different trial blocks. This
requires that the current rule is held in mind and that the rel-
evant digit is updated from trial to trial. However, the task also
draws on other cognitive processes such as response inhibition,
strategy formation and checking. Spatial working memory
involves remembering locations of objects. Computerized
tasks such as the Cambridge Automated Test Battery
(CANTAB) (Cohen and Servan-Schreiber, 1992) often require
a visual search of locations to collect a target object. These,
now empty, locations need to be avoided to efficiently collect
remaining targets. Thus a constant updating of memory of
searched locations is required. Again processes such as strategy
formation and behavioural inhibition are required.
Construct validity. Classic, single cell recoding experiments
in primates by Goldman-Rakic showed that cells in the dorso-
lateral prefrontal cortex represent the spatial location of a cue
over shortdelaysuntil the information isused toobtainareward
(Goldman-Rakic, 1994).Functional imaging studies in humans
confirm that working memory paradigms engage a dorsal net-
work including dorsolateral prefrontal cortex and that these
responses are abnormal in schizophrenia (Callicott et al., 2003).
Criterion validity
Patients, relatives and high schizotypes. Meta-analyses
have indicated that patients with schizophrenia are signifi-
cantly impaired on both verbal and visuo-spatial WM tasks
(Lee and Park, 2005). WM deficits are stable across time and
fluctuations in clinical status (Hill et al., 2004) and are present
before the initiation of treatment (Barch et al., 2001). First-
degree relatives also appear to be affected, with effect sizes
ranging from small to moderate (Snitz et al., 2006). WM def-
icits have also been reported in schizotypal individuals with
(Johnson et al., 2003) and without (Park and McTigue, 1997)
family history of schizophrenia. Although WM is strongly
correlated with IQ, deficits that survive correction for reduced
IQ have been reported in patients and high-risk subjects
(O’Connor et al., 2009; Zanelli et al., 2010).
Glutamate antagonist challenges. Most studies in healthy
volunteers have shown that ketamine impairs WM perfor-
mance, the effects being stronger when the task requires
manipulation of information; affinities with the WM deficits
of schizophrenia have been noted (Fletcher and Honey, 2006,
Morgan and Curran, 2006).
Predictive validity
Dopamine antagonists. Studies in patients treated both
acutely and chronically with typical antipsychotics have
found no beneficial effect on cognitive function (Meltzer
and McGurk, 1999), although positive findings have also
been reported (Keefe et al., 2007). The benefit of atypical
antipsychotic therapy on WM is most likely to be marginal
(Heinrichs, 2005) despite some studies reporting modest
improvement (Houthoofd et al., 2008; Meltzer and
McGurk, 1999; Purdon, 1999).
Dopamine agonists. In healthy volunteers, compounds that
increase dopamine activity have generally been shown to
improve WM. Amphetamine has been demonstrated to
improve WM, especially in those individuals with low base-
line performance (Mattay et al., 1996, 2000). Similar effects
are reported with methylphenidate (Elliott et al., 1997, Mehta
et al., 2000; but see Turner et al., 2003). The selective D2
agonist, bromocriptine, also improved performance on spatial
WM tasks (Kimberg et al., 1997; Luciana et al., 1998; but see
Kimberg et al., 2001). The mixed results of D2 agonism could
be interpreted in the framework that sees D1 receptor agon-
ism as the key factor in cognition enhancement. In demon-
stration of this, the disruption of WM induced in healthy
volunteers by a D2 antagonist challenge was alleviated by
pergolide, a mixed D1/D2 agonist, but not the D2 agonist
bromocriptine (Muller et al., 1998).
There are almost no studies testing the prediction that
dopamine agonists, by reversing the putative deficits in fron-
tal dopamine function, would improve WM in schizophrenia.
The obvious risk would be that psychotic symptoms would be
exacerbated. One study reported that a single dose of amphet-
amine enhanced WM performance in schizophrenic patients
taking antipsychotics (Barch and Carter, 2005). However,
data have emerged on the efficacy of dopamine agonists in
improving WM in schizotypal personality disorder (SPD).
First, acute amphetamine benefited WM in SPD but not in
other personality disorders (Kirrane et al., 2000). Again, the
poorer baseline performers improved the most. Enhancement
of cognition in SPD by dopamine agonism may also hold true
for chronic treatment, as pergolide improved WM after
4 weeks’ treatment in SPD (McClure et al., 2010).
Other agents. Cholinergic drugs modulate WM perfor-
mance. Both muscarinic and nicotinic receptor antagonists
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impair WM performance in healthy volunteers (Green et al.,
2005; Thompson et al., 2000). In one study abstinence from
smoking in patients was associated with impaired WM per-
formance but not in non-schizophrenic smokers and this was
reversed with smoking reinstatement (Sacco et al., 2005).
Freedman et al. (2008) reported beneficial effects of a novel
nicotinic agonist on some measures of WM in non-smoking
patients along with improved negative symptoms.
Cholinesterase inhibitors, on the other hand, improve WM
in healthy volunteers (Furey et al., 2000a, 2000b). Studies
exploring the potential of compounds stimulating the cholin-
ergic system as an adjuvant therapy in patients largely report
improved executive function (Ribeiz et al., 2010).
There is much interest in the role of impaired GABA func-
tion, possibly driven by deficient NMDA glutamate neuro-
transmission (see below), in the impairment of WM in
schizophrenia. Lewis et al (2008) reported that the alpha-2
GABA-A agonist MK-0777 improved performance in a
N-back task in 9 patients with chronic schizophrenia com-
pared to controls. This was accompanied by changes in
EEG and a continuous performance task (see below). This
study has encouraged a larger clinical study that found no
benefit on cognitive impairment in schizophrenia (Buchanan
et al., 2011). However, sedative effects may have obscured
clinical benefit and further studies with more potent agonists
remain warranted.
Reward learning: the salience attribution test
Schulz et al. (1997) demonstrated that the presentation of
unexpected (i.e. unpredicted) food rewards activates dopa-
mine neurones in experimental animals. This is thought to
act as a ‘prediction error’ or teaching signal. Any initially
neutral cue (stimulus) that predictably precedes a reward
will itself acquire the ability to activate dopamine neurones.
In this way predictive cues become imbued with ‘motivational
salience’ (Berridge and Robinson, 1998) and are able to cap-
ture attention and guide goal-direct behaviour. It has been
hypothesized that in psychosis dysregulated dopamine release
provides an inappropriate prediction error signal during the
processing of irrelevant stimuli. This is thought to result in the
inappropriate assignment of salience to external stimuli and
internal representations such as thoughts or memories
(Kapur, 2003). According to the aberrant salience hypothesis,
delusions and hallucinations form as cognitive misattribu-
tions of the origin and significance of the unusual and
repeated experience of many inappropriately salient stimuli.
Task description. Studies exploring salience attribution use
cognitive psychology paradigms in which stimuli are either
coupled with reward or not. The degree of correct and aber-
rant learning is inferred from behavioural measures, including
choices, reaction times or participant awareness judgements
(Roiser et al., 2009). For example in the Salience Attribution
Test (SAT), coloured images of household objects or animals
are presented prior to responding for possible rewards
(money). One stimulus dimension (e.g. red vs. blue – relevant
dimension) very reliably predicts the availability or non-avail-
ability of money, while the other (e.g. animals vs. household
objects – irrelevant dimension) has no bearing on the out-
come. The rewarded stimulus feature (e.g. blue) promotes
faster responding for reward relative to the unrewarded one
(e.g. red), providing a measure of implicit adaptive (i.e.
appropriate) salience; participants are also able to report
this association overtly using visual analogue scales (explicit
adaptive salience). Faster responding/greater reward rating
occurring to one of the irrelevant features over the other
(e.g. animals faster over household objects) indicates aberrant
salience.
Such a distinction between adaptive and aberrant salience
is important to directly test the aberrant salience hypothesis,
since demonstrating an absence of normal reward processing
is not necessarily directly indicative of the presence of con-
text-inappropriate associations, the central tenet of this
model. The first study to investigate behaviour on the SAT
in patients with schizophrenia reported elevated explicit aber-
rant salience in patients with delusions, but not in those with-
out (Roiser et al., 2009), consistent with the aberrant salience
hypothesis (Kapur, 2003).
Construct validity. In apparent variance with the salience
attribution hypothesis, functional imaging studies report
reduced ventral striatal hemodynamic responses during
reward cue conditions (Juckel et al., 2006b; Schlagenhauf
et al., 2008) in patients with schizophrenia; this effect also
correlated with negative symptoms. The proposed explana-
tion for this paradoxical finding is as follows: in the context
of many stimuli of heightened significance generally, reward-
related cues may not differentially activate the ventral stria-
tum, and thus fail to motivate behaviour (Roiser et al., 2009;
Ziauddeen and Murray, 2010). Furthermore, explicit aberrant
salience in the SAT was associated not only with delusions
but also with negative symptoms (Roiser et al., 2009).
Interestingly, in healthy volunteers, the degree of aberrant
explicit salience correlated with haemodynamic responses in
the prefrontal cortex, hypothesized to contribute to negative
symptoms (Juckel et al., 2006b). Such findings highlight the
importance of the distinction between negative symptoms,
including anhedonia, that are secondary to the psychotic
state, and enduring negative symptoms in the absence of psy-
chosis (primary negative symptoms) that have a separate
pathogenesis that is not responsive to antipsychotic drugs.
The construct validity of the aberrant salience measurements
provided by the SAT has also been investigated using princi-
pal components analysis in healthy volunteers (Schmidt and
Roiser, 2009). This study found that aberrant salience was not
related to potentially confounding measures including WM,
selective attention, latent inhibition or reward learning.
Criterion validity
Patients, relatives and high schizotypes. Studies using
reward-based paradigms have reported consistent abnormal-
ities in patients with schizophrenia (Murray et al., 2008a,
2008b; Waltz and Gold, 2007), especially in those with delu-
sions (Roiser et al., 2009), as mentioned previously. Also,
aberrant salience has recently been linked to high levels of
schizotypy (Housden et al., 2010; Roiser et al., 2009;
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Schmidt and Roiser, 2009). There are currently no data
regarding unaffected relatives of patients with schizophrenia,
but evidence from psychophysical experiments suggests that
abnormalities in reward processing increase linearly with
genetic risk (Glatt et al., 2006).
Predictive validity
Dopamine antagonists. Normalization of aberrant salience
with successful antipsychotic treatment has been reported in
patients using the SAT (Roiser et al., 2009). As predicted by
the aberrant salience hypothesis, patients taking antipsy-
chotics also scored lower on adaptive salience than controls
(Kapur, 2003). In addition, the antipsychotic drugs haloper-
idol (Pessiglione et al., 2006) and olanzapine (Abler et al.,
2007) have been reported to attenuate reward-related
responses in the ventral striatum of healthy volunteers.
However, Juckel and colleagues reported a relative sparing
of striatal reward-related responses in patients administered
atypical but not typical antipsychotic drugs (Juckel et al.,
2006a). More drug studies using the SAT in healthy volun-
teers and criterion groups are required before the predictive
validity of the task can be evaluated.
Dopamine agonists. The role of dopamine in aberrant sal-
ience attribution is supported by a study utilizing amphet-
amine challenge in healthy volunteers, which reported a loss
of specificity of haemodynamic responses in the ventral stri-
atum to rewards relative to punishments (Knutson et al.,
2004). The effect of dopamine agonists on SAT performance
has not yet been investigated.
Biconditional learning
Cohen and Servan-Schreiber (1992) have attempted to
account for a broad range of cognitive deficits observed in
schizophrenia by appealing to a unitary mechanism. They
described the cognitive dysfunction seen in schizophrenia as
a failure to produce the appropriate response as a conse-
quence of an impaired ability to represent, maintain or
apply task-setting information; a process that is thought to
rely on intact function of the prefrontal cortex. Consequently,
the deficits in cognitive performance should be particularly
evident when task-setting cues dictate when different
responses are required to the same stimuli.
Paradigm description. Conditional discrimination para-
digms may be used to assess the way in which task-setting
cues can control performance. In these tasks, participants are
required to learn associations between arbitrary pairs of stim-
uli, or between arbitrary stimuli and responses (e.g. Petrides,
1985). These associations are learned by trial-and-error and
based on feedback, either from the experimenter in human
studies or food reinforcement in animal studies. In a condi-
tional discrimination task, the performance of a particular
response may be appropriate in the presence of a specific cue
but is inappropriate at other times. For example, participants
may learn that in the presence of A, response X (but not Y) is
required, whereas in the presence of B, Y (but not X) is
required. In biconditional discrimination tasks, correct
responses are dictated by the particular combination of cues,
usually represented by AXþ, BX, AY, BYþ, where A, B,
X, Y represent cues, and ‘þ’ and ‘’ respectively represent the
presence and absence of appropriate outcomes.
Validity. There have been few studies in humans. A pilot
study using an allergy prediction task (Aitken et al., 2000),
found patients learned the conditional discrimination less
rapidly than controls (unpublished) and similar findings
occurred in high versus low schizotypes (Haddon et al.,
2011). Glutamatergic and dopaminergic drug effects have
been reported in animals but it remains to seen if they are
reproducible in humans (Dunn and Killcross, 2006).
Perception: signal detection task
The cognitive mechanisms which underpin auditory halluci-
nations may be an extension of normal cognitive processes
(Bentall, 1990). The use of healthy volunteer proxies for hal-
lucinatory phenomena such as inner and imagined speech
have been used in functional imaging studies (Shergill et al.,
2000; Simons et al., 2009). However, the use of a behavioural
task which permits the identification of the cognitive mecha-
nisms underpinning a propensity towards hallucinations
would be most time and cost efficient as a biomarker for
this symptom. The signal detection task (SDT) (Barkus
et al., 2007) aims to objectively determine proneness to audi-
tory hallucinations without using suggestion (Cahill, 1996;
Young et al., 1987).
Paradigm description. Participants are asked to indicate
whether they hear a voice during brief periods of white noise.
There is a voice in 60% of the trials. A third of the voice pre-
sentations are clearly audible while the remainder are at audi-
tory threshold. The clearly audible voices give participants an
indication of what to expect and those presented at auditory
threshold allow for some perceptions to be ambiguous. From
these data four pieces of information are provided (e.g. Green
and Swets, 1966; McNichol, 1972): hits (a voice is present and
participants report hearing it); misses (a voice is present but
participants do not report hearing it); correct rejections (a
voice is not present and the participants do not report hearing
it); and false alarms (a voice is not present but the participant
reports hearing it), which is the putative measure of hallucina-
tory proneness. Measures of sensitivity, specificity and
response bias can be calculated using signal detection theory.
Construct validity. In a small fMRI study, Barkus et al.
(2007) reported that false perceptions (when compared to
hearing a voice which was presented) activated closely similar
areas to those associated with hallucinations in patients with
psychosis (e.g. Simons et al., 2009) including the inferior and
superior temporal gyri and the cingulate. Also, a specific asso-
ciation between positive response bias and hallucinatory
proneness items, rather than items relating to visual or
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thought intrusions into cognition, was reported (Varese et al.,
2010).
Criterion validity
Patients, relatives and high schizotypes. A tendency to
report false alarms has been reported in patients with psycho-
sis who report hallucinations (Bentall et al., 1991; Bentall and
Slade, 1985). A similar pattern has been observed in healthy
volunteers in association with high scores on questionnaire
ratings of hallucinatory proneness or positive schizotypy
(Barkus et al., 2007; Bentall and Slade, 1985; Rankin and
O’Carroll, 1995). Most of these studies report that this ten-
dency exists in the absence of any difference in the ability
to detect a signal, although this is not a consistent finding
(e.g. Boecker et al., 2000). In addition performance on
the SDT also seems to be mediated by age and positive schi-
zotypy in a manner consistent with psychosis risk, that is,
younger participants score higher on positive schizotypy,
reporting more false perceptions than older participants
(Barkus et al., 2011).
Drug-validation studies would be of considerable interest
but have yet to be carried out. Given the focus of this task on
auditory hallucinations samples in these studies should be
recruited on the basis of a propensity towards these symptoms.
Cortical electrophysiology: early sensory event-related
potentials
A number of studies suggest that schizophrenia is associated
with impaired visual sensory perception: deficits have been
demonstrated in motion, contrast sensitivity and spatial dis-
crimination (Javitt, 2009). Event-related potentials (ERPs)
recorded by electroencephalography have the temporal reso-
lution necessary to identify the neural basis and are potential
biomarkers of early sensory processing. Two promising mea-
sures of early sensory processing have been developed in the
auditory and visual modalities, namely mismatch-negativity
(MMN) and P1 potentials. The MMN potential is a negative
ERP wave peaking over the temporal cortical lobes at
150–200ms post-stimulus in response to auditory stimuli
that deviate from an established pattern (Naatanen et al.,
1978). The visual P1 potential is generated by any perceived
visual stimulus. It peaks between 100ms and 150ms and has a
bilateral occipital distribution (Di Russo et al., 2003).
Paradigm description. MMN tasks involve participants
listening to repetitive sound patterns which are infrequently
interrupted by stimuli that deviate in terms of intensity or
duration (Michie, 2001). The process is attention-independent
and the participants are usually instructed to ignore the
sounds while watching a film or reading a book. The visual
P1 wave is typically evoked by watching a black and white
checkerboard pattern repetitively flashed on a screen. The
participants are instructed to ignore these stimuli but are visu-
ally engaged by an attentional task (e.g. pressing a button
whenever an animal appears on the screen) (e.g. Yeap et al.,
2006). In the case of both P1 and MMN the outcome measure
is the peak amplitude or the mean amplitude of a window
centred on the peak of interest.
Construct validity. Functional imaging studies have pro-
vided evidence for reduced activation during perception in
both visual and auditory cortex of patients with schizophre-
nia. In the case of MMN, a combined MEG/fMRI study
demonstrated reduced activity planum temporale (secondary
auditory cortex), an area proposed to be crucial for integra-
tion of auditory stimuli (Kircher et al., 2004). A combined
EEG/fMRI study of early visual potentials in schizophrenia
found reduced activation of the V1 and V2 visual areas
(Martinez et al., 2008). Moreover, the P1 potential is predic-
tive of performance on cognitive tasks that require visual
encoding (Butler et al., 2009; Haenschel et al., 2007). This
has been interpreted as evidence that inefficient encoding con-
tributes to higher-order cognitive deficits. Similarly, the
MMN abnormalities in schizophrenia predict social and
occupational impairment (Light and Braff, 2005).
Criterion validity
Patients, relatives and high schizotypes. MMN is reliably
reduced both in patients (Umbricht and Krljes, 2005) and at-
risk individuals, including unaffected relatives (Michie et al.,
2000), schizotypal individuals (Niznikiewicz et al., 2009) and
children at-risk for schizophrenia (Bar-Haim et al., 2003). In
the visual domain, the P1 potential has been consistently
shown to be of reduced amplitude in patients (Doniger
et al., 2002; Foxe et al., 2005; Schechter et al., 2005; Yeap
et al., 2006), unaffected relatives (Yeap et al., 2006) and,
recently, in high schizotypes (Koychev et al., 2010).
Glutamate challenges. Ketamine challenge in healthy vol-
unteers led to diminished MMN amplitude (Kreitschmann-
Andermahr et al., 2001; Oranje et al., 2000; Umbricht et al.,
2000). No studies of ketamine on visual P1 amplitude in
healthy volunteers have been published but animal data sug-
gests that ketamine may disrupt the neural mechanisms of
sensory information processing (Heggelund and Hartveit,
1990; Kwon et al., 1991).
Predictive validity
Dopamine antagonists. Treatment with typical or newer
antipsychotic drugs has no effect on the MMN abnormality
in patients (Korostenskaja et al., 2005; Schall et al., 1999).
Also, unmedicated and recent-onset patients have a pattern of
MMN and P1 abnormalities similar to these of chronically
medicated patients (Javitt et al., 2000; Umbricht et al., 2006;
Yeap et al., 2008b). Finally, an analysis showed that there is
no relationship between antipsychotic dosage or duration of
treatment and the severity of the P1 potential abnormality
(Yeap et al., 2008a).
Dopamine agonists. There have been no studies on the
effects of acute dopamine agonist challenge in auditory
MMN or P1 ERPs.
Koychev et al. 1215
 at LMU Muenchen on June 13, 2013jop.sagepub.comDownloaded from 
Other agents. Benzodiazepine treatment in patients
with schizophrenia does not alter the MMN deficits (Kasai
et al., 2002).
Cortical electrophysiology: oscillation and
coherence biomarkers
Recent theories attribute the core dysfunction in schizophre-
nia to impaired connectivity between and within brain regions
(Andreasen, 1999; Friston, 2005). The synchrony and coher-
ence of neural oscillations is thought to be a fundamental
mechanism that enables coordinated brain activity. EEG
measures of these processes are therefore a natural target
for schizophrenia research (Fries, 2009). Oscillatory activity
has been divided into low (omega 1–3Hz; theta 4–7Hz; alpha
8–12Hz) and high (beta 13–30Hz; gamma 30–200Hz) fre-
quency bands, a distinction which is thought to reflect differ-
ent aspects of cortical connectivity (Buzsaki, 2006). However,
there is considerable overlap, and the classical cut-offs
between bands are somewhat arbitrary (for reviews see
Uhlhaas et al., 2008; Uhlhaas and Singer, 2010). The oscilla-
tions can be characterized in terms of their power and the
degree to which their phases coincide between trials (phase-
locking factor) or electrodes (coherence). Also, two types of
oscillations are analysed: time-locked (evoked) and non–time-
locked (induced). Evoked oscillations are hypothesized to
represent perceptual binding, while induced ones underlie
cognitive processes (Buzsaki, 2006).
Task description. Neural oscillations are studied using
event-related designs in EEG. Any task that evokes a
repeated uniform cognitive response can be used to probe
connectivity in schizophrenia. WM, perceptual binding and
pattern deviance tasks have been employed in both visual and
auditory domains to study connectivity in schizophrenia.
Construct validity. A number of experiments have demon-
strated a close link between synchronized oscillatory activity
and the preparation, initiation and maintenance of cognitive
and behavioural acts (Varela et al., 2001). Studies in patients
have found that reduced evoked oscillations in the beta and
gamma ranges predict WM impairment on a matching to
sample task (Haenschel et al., 2009). Similarly, the disrup-
tions of the non–time-locked (induced) gamma oscillations
have been linked to impaired performance on several cogni-
tive tasks, suggesting that the neural processes underlying
both induced and evoked oscillatory activity are critical to
higher order cognitive processes (Basar-Eroglu et al., 2007;
Cho et al., 2006).
Criterion validity
Patients, relatives and high schizotypes. Abnormalities of
the gamma, beta and alpha oscillations are well documented
in patients with schizophrenia (Uhlhaas et al., 2008). Evoked
gamma bursts time-locked to auditory and visual stimulation
show reduced power and degree of synchronization in
patients (Haenschel et al., 2009; Spencer et al., 2008;
Uhlhaas and Singer, 2006) and unaffected relatives (Tsai
et al., 2004). In a recently completed analysis, power and
phase abnormalities were found in a sample of schizotypal
individuals (Koychev et al., 2011). The pathogenesis of the
observed oscillatory abnormalities has been attributed to dys-
function within local GABA inhibitory networks that set the
rhythm within neuronal networks, and are deficits in the glu-
tamatergic system which mediates long-distance synchroniza-
tion and/or demyelination that affects the cortico-cortical and
cortico-subcortical connectivity (Uhlhaas et al., 2008).
Glutamate antagonist challenges. A study using ketamine in
a gating auditory paradigm found augmented gamma and
reduced theta response in healthy volunteers (Hong et al.,
2009).
Predictive validity
Dopamine antagonists. Data on modulation of oscillatory
activity by antipsychotic drugs are limited, with one group
reporting reduced gamma activity in patients treated with
atypical antipsychotics (Mayner et al., 2008). However, no
correlation was found between chlorpromazine equivalents
and amplitude of evoked and induced oscillations in patient
samples (Haenschel et al., 2009). Also, gamma band abnor-
malities have been reported in unmedicated patients (Gallinat
et al., 2004).
Dopamine antagonists and other agents. There are currently
no data on the effect of dopamine agonists or other psycho-
active compounds on neural oscillations in humans.
Oculomotor control: saccadic eye movements
The study of eye movements has received much interest in the
validation of potential biomarkers due to findings of various
oculomotor deficits in schizophrenia. The saccadic eye move-
ments (rapid eye movements that allow the fixation of a new
object that has appeared in the visual field) are some of the
most widely studied measures in the context of schizophrenia.
Paradigm description. In the prosaccade task a novel
visual target appears in the periphery and the participants
have to direct their gaze at it. In the antisaccade task the
participants have to inhibit the prosaccadic response to a
new stimulus and instead look at its mirror image location
on the opposite side of the screen. The performance measures
of the task are the number of error prosaccades, the latency
and the spatial accuracy of the mirror antisaccade.
Construct validity. Imaging studies have demonstrated that
the antisaccade is a complex task activating a dorsal fronto-
parietal cortical network as well as subcortical project targets;
specifically, dorsolateral and ventrolateral prefrontal cortex,
frontal and supplementary eye fields, the intraparietal sulcus,
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striatum, and thalamus are involved (Munoz and Everling,
2004). Evidence from structural and functional imaging stud-
ies indicate that the structures underlying the abnormality in
schizophrenia are the frontal cortex (Ettinger et al., 2004) and
the striatum (Raemaekers et al., 2002). Performance on the
task has been demonstrated to have high temporal stability
(Ettinger et al., 2003a). Also, the antisaccade error rate cor-
relates with the measures of executive function in patients
with schizophrenia (Hutton et al., 2004).
Criterion validity
Patients, relatives and high schizotypes. Patients with
schizophrenia have been shown to have normal performance
on the prosaccade task (Haraldsson et al., 2008), although
some reports suggest decreased latencies of the responses
(Reilly et al., 2008). In the antisaccade task, however, they
are consistently impaired, making significantly more errors,
having slower antisaccade latencies, and showing deficits in
calculating the spatial location of the mirror image
(Fukushima et al., 1988; Hutton and Ettinger, 2006).
Unaffected biological relatives and schizotypal individuals
also show impaired antisaccade performance (Calkins et al.,
2004).
Glutamate antagonist challenges. Ketamine studies in
healthy humans have found a decrease in prosaccade velocity
and an increase in saccade latency but only non-significant
impairments in antisaccade performance (Radant et al., 1998,
Weiler et al., 2000). The latter is in contrast to Condy and
colleagues who found that ketamine infusions impaired anti-
saccade performance in non-human primates (Condy et al.,
2005). The discrepancy between studies may reflect the differ-
ent dosages of ketamine that were used.
Predictive validity
Dopamine antagonists. Treatment of patients with schizo-
phrenia with both first and second generation antipsychotics
led to a significant decrease in peak saccade velocity in several
studies, but without major effects on antisaccade error rate or
latency (Muller et al., 1999; Straube et al., 1999). However,
switching from first generation neuroleptics to risperidone
was related to improved antisaccade performance (Burke
and Reveley, 2002). Another longitudinal study showed that
risperidone was associated with improvements in antisaccade
latency whereas haloperidol was not (Harris et al., 2006).
Studies of healthy volunteers have shown dose-dependent
decrease in prosaccade peak velocity and either no effects or
negative effects on antisaccades (Reilly et al., 2008). These
negative effects could be due to the sedating effect of neuro-
leptics, as benzodiazepines have similar effects in healthy vol-
unteers (de Visser et al., 2003). In fact, a reduction of
prosaccade velocity is a highly replicated biomarker of a com-
pound’s sedative effects (de Visser et al., 2003).
Dopamine agonists. Methylphenidate and amphetamine
have been reported to improve antisaccade performance
(Klein et al., 2002; O’Driscoll et al., 2005; Wonodi et al.,
2006). Importantly, beneficial effects of repeated amphet-
amine administration in the study by Wonodi et al. were
seen only in individuals with high levels of schizotypy.
Other agents. Antisaccade performance is also sensitive to
the effects of nicotine (Levin et al., 2006; Newhouse et al.,
2004). In healthy smokers, nicotine reduces the rate of reflex-
ive errors (Rycroft et al., 2006) and the latency of antisac-
cades (Ettinger et al., 2009). Healthy non-smokers also show
reduced antisaccade latency with nicotine (Rycroft et al.,
2007). An fMRI study suggests that the improvements in
antisaccade performance with nicotine may be due to
enhanced neural efficiency in the frontal cortex (Ettinger
et al., 2009). Importantly, nicotine also improves antisaccade
performance in schizophrenia (Depatie et al., 2002, Larrison-
Faucher et al., 2004). Conversely, procyclidine, a cholinergic
antagonist, leads to antisaccade impairments in schizophrenia
(Ettinger et al., 2003b).
Oculomotor control: smooth pursuit eye movements
The first reports of the inability of people with schizophrenia
to eye-track accurately a swinging pendulum date from 1908
(Diefendorf and Dodge, 1908). About 100 years later, deficits
in the smooth pursuit eye movements (SPEMs; slow eye
movements that allow the stabilization of a slowly moving
target on the retina) are some of the most robust findings in
schizophrenia research.
Paradigm description. In the SPEM paradigm, partici-
pants have to follow a small visual target moving at a con-
stant velocity without moving their head. The outcome
measures include the ratio between the speed of the moving
target and the eye movements and the rate of catch-up sac-
cades that that bring the image back onto the fovea.
Construct validity. The existing data indicates that SPEMs
are executed by a circuit linking the visual, mediotemporal
(MT), medial superior temporal (MST), prefrontal and motor
regions of the cortex (Newsome et al., 1988). The deficit in
schizophrenia spectrum individuals has been attributed lar-
gely to dysfunction in frontal (O’Driscoll et al., 1999) and
motion sensitive (Lencer et al., 2003) regions. Similar to the
antisaccade task, smooth pursuit performance has good tem-
poral stability (Ettinger et al., 2003a).
Criterion validity
Patients, relatives and high schizotypes. Patients with
schizophrenia are less able to follow the target accurately
than healthy controls (i.e. they show reduced pursuit gain
and make more catch-up and intrusive saccades) (Campion
et al., 1992; Ross et al., 2002; Trillenberg et al., 2004).
Studies in relatives have found similar deficits in gain
(Ross et al., 2002) and intrusive saccades (Rosenberg et al.,
1997; Ross et al., 2002). Schizotypal individuals have also
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been demonstrated to have smooth pursuit abnormalities
(O’Driscoll et al., 1998; Smyrnis et al., 2007).
Glutamate antagonist challenges. Ketamine challenge stud-
ies have found a range of abnormalities, namely a dose-
dependent nystagmus (Radant et al., 1998), increase in the
number of anticipatory saccades (Avila et al., 2002) and def-
icit in measures that test retinal (but not extraretinal) target
processing (Weiler et al., 2000).
Predictive validity
Dopamine antagonists. Initiation of antipsychotic treat-
ment has been reported to be associated with a decrease of
pursuit gain, indicating a sensorimotor impairment (Lencer
et al., 2008). Chronic treatment appears to have a similar
effect, as long-term medicated patients perform worse than
chronic non-medicated and treated first-episode patients
(Hutton et al., 2001; Sweeney et al., 1999; but see Thaker
et al., 1999). A study administering low doses of haloperidol,
amphetamine and placebo in a sample of healthy volunteers
reported an increase in saccadic intrusions during smooth
pursuit with the haloperidol that was not present in the
other groups (Malaspina et al., 1994). Similar to the antisac-
cade data, the observed effects could at least partly be attrib-
uted to the sedating action of antipsychotics, as
benzodiazepines have been shown to decrease SPEM velocity
in healthy volunteers (Reilly et al., 2008). Also, evidence from
healthy volunteer and schizophrenia studies indicates that
nicotine improves SPEM performance (Domino et al., 1997)
and the anticholinergic compound procyclidine
worsens SPEM performance in schizophrenia (Ettinger
et al., 2003b).
Dopamine agonism. In the only currently available study
the effects of acute amphetamine on SPEMs, no signifi-
cant effect of the challenge was reported (Malaspina et al.,
1994).
Discussion
We have reviewed several cognitive and physiological bio-
markers for schizophrenia for their potential as biomarkers
for drug discovery in healthy volunteers. Several conclusions
can be drawn on the basis of this literature.
Reliability
The MATRICS initiative stands out in terms of demonstrat-
ing reliability – that the same results in terms of group differ-
ences and correlations with outcome are seen in different
centres and across time (Nuechterlein et al., 2008). This has
been driven by the need to find drugs that improve the
cognitive deficits of schizophrenia and to convince licens-
ing authorities and Industry of the validity of MATRICS
tests as markers of efficacy. There have been no other
systematic studies of reliability of the other biomarkers
reviewed.
Surrogate populations
Many of the biomarkers show differences between controls
and criterion groups – patients, unaffected relatives and schi-
zotypal individuals. The lack of institutionalization, chronic
disease and medication in the healthy volunteer groups con-
firms the idea that the abnormalities observed in schizophre-
nia are not due to the confounding factors of illness course
and treatment. Instead, it indicates that cognitive dysfunction
is a core feature of schizophrenia that is present across the
disease spectrum (Heinrichs, 2005). Familial abnormalities
suggest the measures are endophenotypic trait biomarkers.
This is not weakened if the biomarkers are also abnormal
in schizotypal individuals since they may also carry risk
genes (e.g. Fanous and Kendler, 2004). Equally, however,
unaffected family members may have schizotypal features –
this is rarely checked in the literature – so familiality may
involve an element of state-dependency (see Diwadkar
et al., 2006 for effects of familial risk and schizotypy interact-
ing with age for WM performance.
Ketamine as a pharmacological model of schizophrenia
The available data suggests that acute ketamine administra-
tion has a generally mild disruptive effect on neurocognitive
function in humans. The pattern of abnormalities has simi-
larities to those observed in patients, relatives and high schi-
zotypes (Krystal et al., 1999). It has been argued that the
cognitive effects of ketamine and the symptoms it evokes
may more closely mimic deficit symptoms and cognitive
impairment in schizophrenia (Pomarol-Clotet et al., 2006)
and this would be in keeping with the lack of effect of halo-
peridol or clozapine on these phenomena. That ketamine also
mimics some of the GABA/glutamate neurochemical abnor-
malities of schizophrenia suggests that ketamine-evoked bio-
marker changes in volunteers have significant construct
validity.
Dopamine and cognition
Sensitivity to drug challenges aimed at improving cognition
or clinical states was evident with several of the reviewed
biomarkers. The most consistent finding was that dopaminer-
gic treatments generally affect cognitive performance. An
important characteristic is that enhancing dopamine function
tends to selectively improve low baseline performance but
worsen optimal performance. These findings fit in well with
the idea that executive problems in schizophrenia spectrum
disorders are due to suboptimal dopamine activity. Some
authors have proposed a U-shaped curve to describe the rela-
tionship between dopamine and executive function, with
hypo- and hyperdopaminergic states leading to cognitive
abnormalities (Barch, 2004). The proposed suboptimal dopa-
mine function in the schizophrenia-spectrum has been attrib-
uted to the high activity version (val/val genotype) of the
enzyme that metabolizes dopamine, namely catechol-
O-methyl transferase (COMT). In support of this, tolcapone,
an inhibitor of COMT, improved N-back performance in
healthy volunteers at high loads (Mattay et al., 2000). Also,
participants with the val/val genotype benefited preferentially
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from treatment with tolcapone in an episodic memory task. In
a different study, low WM performance in val/val participants
was improved by a challenge with dextroamphetamine. The
same agent led to deterioration at high WM capacity in par-
ticipants with the met/met genotype (Fava et al., 1999).
Abnormalities in other enzymes involved in clearing dopa-
mine from the synaptic cleft have also been implicated, but
evidence for direct involvement in schizophrenia spectrum
pathophysiology is scarce (Apud and Weinberger, 2006).
A second important feature of dopamine effects is that D1
agonists appear to be more effective than D2 agonists, and
this may reflect the greater concentration of D1 receptors
compared with D2 receptors in the prefrontal cortex. The
implication of these findings is that frontal dopamine neuro-
transmission is a validated target for future drug development
and a promising line of development.
Also, the improvement of some of the biomarkers by com-
pounds affecting non-dopamine neurotransmitter systems in
healthy volunteers (such as the benefit to eye-tracking perfor-
mance by cholinergic agonists) suggest that cognitive pro-
cesses may have a variety neuromodulatory influences, so
possible drug targets are not limited to the most commonly
explored dopaminergic and glutamatergic systems.
State and trait biomarkers
The reviewed literature showed a variable relationship
between clinical state and biomarker performance; some bio-
markers showed a degree of state dependency whereas others
did not. The state-dependent biomarkers included salience
attribution, eye-tracking and perhaps WM tasks where
there is some evidence for varying degrees of improvement
with atypical antipsychotics. This effect could be due to their
lower affinity for the D2 receptor, which may permit endog-
enous dopamine activity (Kapur and Remington, 2001). This
might be particularly important for prefrontal cortical func-
tion, and the performance on tasks that depend on its integ-
rity, such as WM and eye-tracking, reflects this. In support of
this, no improvement is found with typical antipsychotics,
despite their efficacy in controlling positive symptoms. The
practical implication of such biomarkers is that they could
potentially be validated as clinical end-points to assess effi-
cacy of agents that ameliorate both cognitive impairment and
psychosis.
Measures such as early sensory event-related potentials
and oscillations were generally not influenced by antipsy-
chotic treatment or clinical state. This indicates that the
underlying abnormality is probably state-independent and
related to factors predisposing to schizophrenia. Findings
of similar abnormalities in individuals at genetic or psycho-
pathological risk for schizophrenia support this. ERPs and
oscillatory synchrony and coherence can be informative
about neural connectivity, dysfunction in which has been
argued to be a core feature of schizophrenia. In other
words the biomarkers relate to a neural process implicated
in pathogenesis and so have some construct validity. Using
such measures as biomarkers in drug development would
be most useful in assessing novel agents that aim to modify
the disease process through regulating connectivity. They
have no use in detecting drugs that are variations on
existing antipsychotic drugs with action on dopamine.
There is as yet little information about drug effects on
EEG measures and this is an important priority for
future research.
The state/trait distinction is not cut and dried. For exam-
ple, despite the modest data suggesting improvement of WM
and eye-tracking performance with atypical antipsychotic
treatment, these deficits are still found in first-degree relatives.
This indicates that they are at least to a certain extent inde-
pendent from clinical state and are likely to persist in a milder
form even when complete remission is achieved. Trait bio-
markers have the potential to detect drugs that prevent
onset of psychosis by acting on mechanisms of vulnerability
that may be distinct from mechanisms of the symptomatic
state.
Some studies suggest that biomarkers in the proposed
target groups may have predictive utility for drug develop-
ment. For example, McClure et al. (2010) showed that pergo-
lide improved visual–spatial WM in a small sample of 25
people with Schizotypal Personality Disorder (diagnosed
according to the Diagnostic and Statistical Manual of
Mental Disorders, 4th edition (DSM-IV)) when given for a
short period of 4 weeks. This cognitive benefit was also asso-
ciated with symptomatic improvement.
Future directions
One of the clear priorities of future research is the develop-
ment of non-dopaminergic agents that are effective in treating
the cognitive and psychotic features of schizophrenia. As
argued previously, the proposed biomarkers can assist in
this endeavour by allowing early proof-of-concept studies in
surrogate populations. However, as the spectrum of clinical
efficacy of such compounds emerges they will help to validate
biomarkers for drugs targeting different aspects of
schizophrenia.
There is a clear need for more data on the reliability of the
measures especially for the non-MATRICS biomarkers and
for data about drug actions on the novel biomarkers (SDT,
SAT) and the EEG measures. Further, standardized proce-
dures need to be agreed on and established in each task. These
are all key prerequisites in order for large, multi-site screening
of novel compounds to take place.
Further validation of biomarkers can be achieved through
prospective clinical trials in target groups such as unaffected
relatives and high schizotypes. For example, McClure and
colleagues show that such design can give a more clinically
relevant picture of the properties of the drug and the bio-
marker than the trials where acute drug administration
takes place (McClure et al., 2010).
From the basic science point of view, more research is
needed into the pathophysiology of the cognitive mechanisms
that underlie the biomarkers. Dissecting the neurophysiolog-
ical and molecular bases of the different components of com-
plex functions such as WM could reveal a number of
prospective targets for drug development. Such informed
approach to research and development will benefit from the
possibility for quick validation of the resulting compound
with the biomarker that they were derived from (in this
case, WM).
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Finally, imaging techniques such as fMRI and PET
are an exciting field for cognitive biomarker research.
However, more research is needed to identify reliable and
pathophysiologically relevant outcome measures that will be
useful in the settings of a clinical trial.
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